Inicio>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Leu-AMS

Leu-AMS

Catalog No.GC32121

Leu-AMS (compuesto 6), un anÁlogo de leucina, es un potente inhibidor de la leucil-tRNA sintetasa (LRS) con una IC50 de 22,34 nM, que inhibe la actividad catalÍtica de LRS pero no afecta la activaciÓn de mTORC1 inducida por leucina.

Products are for research use only. Not for human use. We do not sell to patients.

Leu-AMS Chemical Structure

Cas No.: 288591-93-5

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
548,00 $
Disponible
1mg
175,00 $
Disponible
5mg
543,00 $
Disponible
10mg
818,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Leu-AMS is a potent inhibitor of leucyl-tRNA synthetase (LRS) with an IC50 of 22.34 nM and inhibits the growth of bacteria.

Leu-AMS is proved to be a potent inhibitor of Leucyl-tRNA Synthetase (LRS) with an IC50 value of 22.34 nM. Leu-AMS is highly cytotoxic in both cancer cells and normal cells. Leu-AMS does not affect S6 kinase (S6K) phosphorylation at all. Leu-AMS inhibits the catalytic activity of LRS but does not affect the leucine-induced mTORC1 activation[1].

[1]. Yoon S, et al. Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-TargetedMammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors. J Med Chem. 2016 Nov 23;59(22):10322-10328.

Reseñas

Review for Leu-AMS

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Leu-AMS

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.